Chimeric Antig en Receptor T-cell (CAR T) therapy has revolutionized the treatment of certain hematological malignancies, offering hope for patients with refractory or relapsed cancers. As the use of CAR T cells becomes more widespread, effective methods for monitoring and detecting these engineered cells are critical for optimizing therapy and ensuring patient safety.